In order to investigate the relationship between HBV and hepatocellular carcinoma(HCC),hepatitis B virus DNA(HBV DNA),HBxAg and HBcAg were detected in 44 paraffin-embedded samples of HCC tissue(17 cases with cancer-su...In order to investigate the relationship between HBV and hepatocellular carcinoma(HCC),hepatitis B virus DNA(HBV DNA),HBxAg and HBcAg were detected in 44 paraffin-embedded samples of HCC tissue(17 cases with cancer-surrounding hepatic tissues) and 42 case展开更多
Hepatitis B virus (HBV) infection has long been a critical public health challenge in China. National surveys revealed a prevalence of approximate 10% for chronic HBV infection in general population. HBV has been the ...Hepatitis B virus (HBV) infection has long been a critical public health challenge in China. National surveys revealed a prevalence of approximate 10% for chronic HBV infection in general population. HBV has been the leading cause of chronic hepatitis, cirrhosis, and liver cancers in Chinese population and a common pathogen of acute viral hepatitis. Meanwhile, the epidemic provided important opportunities to research the natural history, public health impact, and therapeutic and preventive interventions for HBV in China. In this review, we summarized the selected key epidemiological studies since 1970s regarding HBV infection and its associated liver diseases in China, and provided considerations for future research, prevention and treatment of HBV.展开更多
The expression of p53 protein was examined immunohistochemically in 80 cases of huamn primary hepatocellular carcinoma (HCC) to assess its prevalence and the relationship between p53 overexpression and the clinicopath...The expression of p53 protein was examined immunohistochemically in 80 cases of huamn primary hepatocellular carcinoma (HCC) to assess its prevalence and the relationship between p53 overexpression and the clinicopathological features of HCC. It was found that nuclear immunostaining of the hepatocytes for p53 was positive in 35 cases out of the 80 and none of the cells of the surrounding non-cancerous tissue was immunostaining positive.The detection rate of p53 was significantly higher in cases with metastasis than in those without. No relationship was found between the overexpression of p53 and the size and differentiation of HCC. The expression of p53 protein was more commonly found in those cases with the history of HBV infection but the difference was not statistically significant. These findings indicate that the overexpression of p53 will not definitely occur in the late stage of HCC but it may be a sign of the aggressive phenotype of HCC existing in the early stage of the carcinoma. Our results support the postulation that the common effects of HBV and aflatoxin result in the generation of p53 gene mutation in HCC.展开更多
目的:采用网络药理学方法研究茵黄解毒汤治疗乙型肝炎病毒(hepatitis B virus,HBV)相关肝衰竭(hepatitis B virus related liver failure,HBV-LF)的活性成分及其分子机制。方法:采用GEO数据库筛选疾病相关差异基因(differentially expre...目的:采用网络药理学方法研究茵黄解毒汤治疗乙型肝炎病毒(hepatitis B virus,HBV)相关肝衰竭(hepatitis B virus related liver failure,HBV-LF)的活性成分及其分子机制。方法:采用GEO数据库筛选疾病相关差异基因(differentially expressed genes,DEGs),TCMSP数据库筛选中药复方小分子化合物及其作用靶点,Venny 2.1.0进行交集比对,确定交集靶点及其关系。运用Cytoscape构建茵黄解毒汤治疗HBV-LF的调控网络,Bisogenet构建蛋白互作网络(protein-protein interaction network,PPI),CytoNCA进行网络拓扑学分析。利用David数据库进行GO富集分析和KEGG信号通路富集分析。结果:本研究共得到HBV-LF的差异基因2160个,茵黄连解毒汤的药物靶点255个,交集靶点31个,相关小分子化合物66个。小分子化合物包括槲皮素、山柰酚、黄芩素、芦荟大黄素、黄连素等。PPI网络涉及55个关键节点,包括TP53、NTRK1、HSP90AA1、ESR1、CUL3、MCM2、CDK2、HSP90AB1、YWHAZ、NPM1、EGFR等。GO富集分析主要与细胞组分构成或来源、对刺激的反应、免疫过程、正/负调节的生物过程、细胞死亡、细胞增殖等有关。KEGG通路27条,主要涉及PI3K-Akt信号通路、MAPK信号通路、Cell cycle、Hepatitis B、自噬、FoxO信号通路、Ras信号通路、IL-17信号通路、NOD样受体信号通路、HIF-1信号通路、NF-κB信号通路等。结论:茵黄解毒汤拮抗HBVLF具有“多靶点-多通路-多作用”的特性,其作用机制可能与促进肝细胞增殖分化、降低肝细胞凋亡、调节机体免疫、抑制HBV复制等有关。展开更多
目的探讨乙肝相关性肝癌(HCC)患者术前HBV-DNA载量水平与术后肝功能恢复的关系。方法将56例行肝癌根治术的HCC患者按术前血清中HBV-DNA载量分为低复制组(血清HBV-DNA载量≤104IU/ml,n=35)和高复制组(血清HBV-DNA载量≥105IU/ml,n=21),...目的探讨乙肝相关性肝癌(HCC)患者术前HBV-DNA载量水平与术后肝功能恢复的关系。方法将56例行肝癌根治术的HCC患者按术前血清中HBV-DNA载量分为低复制组(血清HBV-DNA载量≤104IU/ml,n=35)和高复制组(血清HBV-DNA载量≥105IU/ml,n=21),观察比较术前3 d和术后7 d HBV-DNA载量变化例数及ALT、AST、ALB、TBIL等肝功能指标变化、肝功能恢复时间,同时记录两组患术后并发症发生情况。结果两组患者手术前、后血清中HBV-DNA载量无显著性变化(P>0.05),两组患者术后7 d ALT、AST、TBIL指标较术前3 d显著升高(P<0.05),而三组术后ALB指标较治疗前显著降低(P<0.05),且高复制组ALT、AST指标显著高于低复制组(P<0.05),而两组在ALB和ABIL等指标比较,差异不具有统计学意义(P>0.05)。而低复制组肝功能恢复天数显著短于高复制组,差异具有统计学意义(P<0.05)。高复制组患者术后并发症(47.62%)显著高于低复制组患者(17.14%),差异具有统计学意义(P<0.05)。结论 HCC患者术前血清HBV-DNA的高水平载量将显著延长患者术后肝功能恢复时间,同时增加患者术后并发症发生风险。展开更多
目的探讨乙肝病毒X蛋白(hepatitis B virus X protein,HBx)与缺氧诱导因子-1α(hypoxia-inducible factor,HIF-1α)在乙肝相关性肝细胞肝癌(hepatocellular carcinoma,HCC)组织血管生成及转移中的作用。方法选择84例乙肝相关性肝癌组织...目的探讨乙肝病毒X蛋白(hepatitis B virus X protein,HBx)与缺氧诱导因子-1α(hypoxia-inducible factor,HIF-1α)在乙肝相关性肝细胞肝癌(hepatocellular carcinoma,HCC)组织血管生成及转移中的作用。方法选择84例乙肝相关性肝癌组织和22例非乙肝相关性肝癌组织,免疫组化法检测HBx、HIF-1α及血管内皮细胞表面抗原(CD34)表达,光镜下记录微血管计数(microvessel density,MVD)。结果 84例乙肝相关性肝癌组织中HBx阳性表达率为73.81%(62/84)。62例HBx阳性表达组中的HIF-1α阳性率为69.35%(43/62),明显高于HBx阴性组40.91%(9/22)和非乙肝相关性肝癌组36.36%(8/22)(P<0.05)。HBx阴性表达的乙肝相关性肝癌组和非乙肝相关性肝癌组中HIF-1α阳性表达无统计学意义(P>0.05)。HBx和HIF-1α的表达呈正相关(rs=0.573,P<0.01);HBx和HIF-1α在高分化肿瘤组织中的表达高于低分化组织(P<0.05),且转移组表达高于无转移组;HBx阳性表达组平均MVD值明显高于HBx阴性组和非乙肝相关性肝癌组(P<0.01),有转移组MVD高于无转移组(P<0.01);有门脉侵犯组高于非侵犯组(P<0.05)。结论 HBx和HIF-1α广泛表达于乙肝相关性肝癌组织中,二者呈正相关;HBx可能通过上调HIF-1α的表达在乙肝相关性肝癌组织血管生成及转移中起促进作用。展开更多
文摘In order to investigate the relationship between HBV and hepatocellular carcinoma(HCC),hepatitis B virus DNA(HBV DNA),HBxAg and HBcAg were detected in 44 paraffin-embedded samples of HCC tissue(17 cases with cancer-surrounding hepatic tissues) and 42 case
文摘Hepatitis B virus (HBV) infection has long been a critical public health challenge in China. National surveys revealed a prevalence of approximate 10% for chronic HBV infection in general population. HBV has been the leading cause of chronic hepatitis, cirrhosis, and liver cancers in Chinese population and a common pathogen of acute viral hepatitis. Meanwhile, the epidemic provided important opportunities to research the natural history, public health impact, and therapeutic and preventive interventions for HBV in China. In this review, we summarized the selected key epidemiological studies since 1970s regarding HBV infection and its associated liver diseases in China, and provided considerations for future research, prevention and treatment of HBV.
文摘The expression of p53 protein was examined immunohistochemically in 80 cases of huamn primary hepatocellular carcinoma (HCC) to assess its prevalence and the relationship between p53 overexpression and the clinicopathological features of HCC. It was found that nuclear immunostaining of the hepatocytes for p53 was positive in 35 cases out of the 80 and none of the cells of the surrounding non-cancerous tissue was immunostaining positive.The detection rate of p53 was significantly higher in cases with metastasis than in those without. No relationship was found between the overexpression of p53 and the size and differentiation of HCC. The expression of p53 protein was more commonly found in those cases with the history of HBV infection but the difference was not statistically significant. These findings indicate that the overexpression of p53 will not definitely occur in the late stage of HCC but it may be a sign of the aggressive phenotype of HCC existing in the early stage of the carcinoma. Our results support the postulation that the common effects of HBV and aflatoxin result in the generation of p53 gene mutation in HCC.
文摘目的:采用网络药理学方法研究茵黄解毒汤治疗乙型肝炎病毒(hepatitis B virus,HBV)相关肝衰竭(hepatitis B virus related liver failure,HBV-LF)的活性成分及其分子机制。方法:采用GEO数据库筛选疾病相关差异基因(differentially expressed genes,DEGs),TCMSP数据库筛选中药复方小分子化合物及其作用靶点,Venny 2.1.0进行交集比对,确定交集靶点及其关系。运用Cytoscape构建茵黄解毒汤治疗HBV-LF的调控网络,Bisogenet构建蛋白互作网络(protein-protein interaction network,PPI),CytoNCA进行网络拓扑学分析。利用David数据库进行GO富集分析和KEGG信号通路富集分析。结果:本研究共得到HBV-LF的差异基因2160个,茵黄连解毒汤的药物靶点255个,交集靶点31个,相关小分子化合物66个。小分子化合物包括槲皮素、山柰酚、黄芩素、芦荟大黄素、黄连素等。PPI网络涉及55个关键节点,包括TP53、NTRK1、HSP90AA1、ESR1、CUL3、MCM2、CDK2、HSP90AB1、YWHAZ、NPM1、EGFR等。GO富集分析主要与细胞组分构成或来源、对刺激的反应、免疫过程、正/负调节的生物过程、细胞死亡、细胞增殖等有关。KEGG通路27条,主要涉及PI3K-Akt信号通路、MAPK信号通路、Cell cycle、Hepatitis B、自噬、FoxO信号通路、Ras信号通路、IL-17信号通路、NOD样受体信号通路、HIF-1信号通路、NF-κB信号通路等。结论:茵黄解毒汤拮抗HBVLF具有“多靶点-多通路-多作用”的特性,其作用机制可能与促进肝细胞增殖分化、降低肝细胞凋亡、调节机体免疫、抑制HBV复制等有关。
文摘目的探讨乙肝相关性肝癌(HCC)患者术前HBV-DNA载量水平与术后肝功能恢复的关系。方法将56例行肝癌根治术的HCC患者按术前血清中HBV-DNA载量分为低复制组(血清HBV-DNA载量≤104IU/ml,n=35)和高复制组(血清HBV-DNA载量≥105IU/ml,n=21),观察比较术前3 d和术后7 d HBV-DNA载量变化例数及ALT、AST、ALB、TBIL等肝功能指标变化、肝功能恢复时间,同时记录两组患术后并发症发生情况。结果两组患者手术前、后血清中HBV-DNA载量无显著性变化(P>0.05),两组患者术后7 d ALT、AST、TBIL指标较术前3 d显著升高(P<0.05),而三组术后ALB指标较治疗前显著降低(P<0.05),且高复制组ALT、AST指标显著高于低复制组(P<0.05),而两组在ALB和ABIL等指标比较,差异不具有统计学意义(P>0.05)。而低复制组肝功能恢复天数显著短于高复制组,差异具有统计学意义(P<0.05)。高复制组患者术后并发症(47.62%)显著高于低复制组患者(17.14%),差异具有统计学意义(P<0.05)。结论 HCC患者术前血清HBV-DNA的高水平载量将显著延长患者术后肝功能恢复时间,同时增加患者术后并发症发生风险。
文摘目的探讨乙肝病毒X蛋白(hepatitis B virus X protein,HBx)与缺氧诱导因子-1α(hypoxia-inducible factor,HIF-1α)在乙肝相关性肝细胞肝癌(hepatocellular carcinoma,HCC)组织血管生成及转移中的作用。方法选择84例乙肝相关性肝癌组织和22例非乙肝相关性肝癌组织,免疫组化法检测HBx、HIF-1α及血管内皮细胞表面抗原(CD34)表达,光镜下记录微血管计数(microvessel density,MVD)。结果 84例乙肝相关性肝癌组织中HBx阳性表达率为73.81%(62/84)。62例HBx阳性表达组中的HIF-1α阳性率为69.35%(43/62),明显高于HBx阴性组40.91%(9/22)和非乙肝相关性肝癌组36.36%(8/22)(P<0.05)。HBx阴性表达的乙肝相关性肝癌组和非乙肝相关性肝癌组中HIF-1α阳性表达无统计学意义(P>0.05)。HBx和HIF-1α的表达呈正相关(rs=0.573,P<0.01);HBx和HIF-1α在高分化肿瘤组织中的表达高于低分化组织(P<0.05),且转移组表达高于无转移组;HBx阳性表达组平均MVD值明显高于HBx阴性组和非乙肝相关性肝癌组(P<0.01),有转移组MVD高于无转移组(P<0.01);有门脉侵犯组高于非侵犯组(P<0.05)。结论 HBx和HIF-1α广泛表达于乙肝相关性肝癌组织中,二者呈正相关;HBx可能通过上调HIF-1α的表达在乙肝相关性肝癌组织血管生成及转移中起促进作用。
